These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37010875)

  • 1. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
    Plotkin SR; Allen J; Dhall G; Campian JL; Clapp DW; Fisher MJ; Jain RK; Tonsgard J; Ullrich NJ; Thomas C; Edwards LJ; Korf B; Packer R; Karajannis MA; Blakeley JO
    Neuro Oncol; 2023 Aug; 25(8):1498-1506. PubMed ID: 37010875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
    Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
    J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
    Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
    J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2.
    Huang V; Bergner AL; Halpin C; Merker VL; Sheridan MR; Widemann BC; Blakeley JO; Plotkin SR
    Otol Neurotol; 2018 Jun; 39(5):632-638. PubMed ID: 29649040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
    Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
    Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
    Plotkin SR; Halpin C; McKenna MJ; Loeffler JS; Batchelor TT; Barker FG
    Otol Neurotol; 2010 Sep; 31(7):1135-43. PubMed ID: 20736812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
    Nghiemphu PL; Vitte J; Dombi E; Nguyen T; Wagle N; Ishiyama A; Sepahdari AR; Cachia D; Widemann BC; Brackmann DE; Doherty JK; Kalamarides M; Giovannini M
    J Neurooncol; 2024 Apr; 167(2):339-348. PubMed ID: 38372904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
    Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
    J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality.
    Gugel I; Zipfel J; Hartjen P; Kluwe L; Tatagiba M; Mautner VF; Schuhmann MU
    Childs Nerv Syst; 2020 Oct; 36(10):2471-2480. PubMed ID: 32548671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes.
    Lu VM; Ravindran K; Graffeo CS; Perry A; Van Gompel JJ; Daniels DJ; Link MJ
    J Neurooncol; 2019 Sep; 144(2):239-248. PubMed ID: 31254266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma.
    Fujii M; Kobayakawa M; Saito K; Inano A; Morita A; Hasegawa M; Mukasa A; Mitsuhara T; Goto T; Yamaguchi S; Tamiya T; Nakatomi H; Oya S; Takahashi F; Sato T; Bakhit M; On Behalf Of The BeatNF Trial Investigators
    Curr Oncol; 2021 Jan; 28(1):726-739. PubMed ID: 33572546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities.
    Sverak P; Adams ME; Haines SJ; Levine SC; Nascene D; Sommer K; Dusenbery K; Huang TC; Moertel C
    Otolaryngol Head Neck Surg; 2019 Mar; 160(3):526-532. PubMed ID: 30373466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case Series.
    Douwes JPJ; Koetsier KS; van Dam VS; Plotkin SR; Barker FG; Welling DB; Jansen JC; Hensen EF; Shih HA
    Curr Oncol; 2023 Mar; 30(3):3473-3483. PubMed ID: 36975476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.
    Karajannis MA; Legault G; Hagiwara M; Ballas MS; Brown K; Nusbaum AO; Hochman T; Goldberg JD; Koch KM; Golfinos JG; Roland JT; Allen JC
    Neuro Oncol; 2012 Sep; 14(9):1163-70. PubMed ID: 22844108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
    Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
    Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
    Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
    Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence.
    Renzi S; Michaeli O; Salvador H; Alderete D; Ponce NF; Zapotocky M; Hansford JR; Malalasekera VS; Toledano H; Maguire B; Bouffet E; Ramaswamy V; Baroni LV
    Pediatr Blood Cancer; 2020 May; 67(5):e28228. PubMed ID: 32124552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
    Sponghini AP; Platini F; Rondonotti D; Soffietti R
    Tumori; 2015 Nov; 101(6):e167-70. PubMed ID: 26108240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
    Fisher LM; Doherty JK; Lev MH; Slattery WH
    Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
    Plotkin SR; Stemmer-Rachamimov AO; Barker FG; Halpin C; Padera TP; Tyrrell A; Sorensen AG; Jain RK; di Tomaso E
    N Engl J Med; 2009 Jul; 361(4):358-67. PubMed ID: 19587327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.